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ABSTRACT
Although neuroblastoma is a relatively common malignancy of childhood and its dissemination to distant organs is 
often seen, metastasis to the mandible is rare. A 3-year-old boy which a mandibular soft tissue mass was the initial pre-
senting symptom of disseminated neuroblastoma is reported. The results of biopsy were inconclusive and the differential 
diagnosis from the imaging studies included lymphoma, soft tissue sarcoma, and osteosarcoma. A metastatic work-up 
disclosed neuroblastoma of the adrenal gland origin with osseous and bone marrow metastases. Urinary catecolamines 
were also increased. Regarding the widespread features of the tumor and lack of adequate treatment at this stage of 
disease, a palliative chemotherapy was conducted, and the patient died one month after starting treatment. This case 
illustrates that neuroblastoma at a young age, with bone metastases and bone marrow involvement are predictive of the 
poor outcome of the disease. Therefore, detecting early stage metastasis is one of the essential factors for improving 
treatment of neuroblastoma patients. 
Key words: Neuroblastoma, metastasis, mandible.
Indexed in: 
-Index Medicus / MEDLINE  /  PubMed            
-EMBASE, Excerpta Medica
-SCOPUS
-Indice Médico Español                                                        
-IBECS
INTRODUCTION
Neuroblastic tumors are a heterogeneous group of 
embryonal tumors derived from the neural crest cells. 
Neuroblastoma accounts for 10-15% of all childhood malig-
nancies. The median age at diagnosis is 22 months, and more 
than 95% of cases are diagnosed by 10 years of age (1). 
Histologically, the International Neuroblastoma Pathology 
Committee (2) proposed three basic morphologic patterns: 
neuroblastoma (NB), ganglioneuroma (GN) and ganglio-
neuroblastoma (GNB). These tumors have a variety of 
clinical behaviors, from spontaneous regression or differen-
tiation to early metastasis and death (2,3). Neuroblastoma 
is the most immature and undifferentiated form (of  the 
three) with a high propensity to metastasis. Dissemination 
to bones, skull and lymph nodes has been well described 
(4,5). However, an unusual presentation such as the man-
dible is rare. 
In this paper, we report a rare case of an adrenal neuroblas-
toma with metastasis to the mandible. We discuss clinicopa-
thologic features, biologic behaviour and prognostic factor 
of neuroblastoma. 
CASE REPORT
A 3-year-old boy was referred to our department for diag-
nosis and treatment of anaemia, generalised bone pain, a 
swelling of the left mandible (Fig. 1) with teeth displace-
ment. Empiric treatment of symptoms failed to control the 
continuing pain and the progressively enlarging intraoral 
mass.  (Fig 2) 
On clinical examination, the patient was found to have a 
firm, non-tender, and fixed mass on the left body of the 
mandible. The buccal mucosa overlying the mass was 
erythematous, swollen and extended to the occlusal surfaces 
of the mandibular molars. This was associated with mild 
(left) facial asymmetry. Multiple enlarged cervical lymph 
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nodes were palpable bilaterally.
Computed tomography scans revealed invasion of the left 
mandibular bone with lytic destruction measuring 4,6×4,9 
cm with involvement of  the masseter and the lateral 
pterygoid muscles and extension into the infratemporal fossa 
(Fig 3). A fine needle aspiration biopsy of the tumor was 
performed twice, but both specimens were inconclusive. 
At the time of his admission, there were also some labo-
ratory abnormalities: hemoglobin (Hb) 7,5 g/dl, Mean 
corpuscular volume (MCV) 63 µm3, platelet count (PLT) 
250x109/l, Glutamyl oxaloacetic transaminase (GOT) 106 
I.U/l, Glutamyl pyruvic transaminase (GPT) 220 I.U/l, and 
α-fetoprotein (ALP) 196 I.U/L. Urinary homovanillic acid 
(HVA) was increased to 35 mg/day. 
Given these findings, a metastatic work-up was performed 
to assess the location and extent of both primary and metas-
tatic lesions. Ultrasound abdominal radiography identified 
a 8,9×6,6×7,8 cm nonhomogenous left adrenal tumor, and 
paraaortic lymph nodes in close proximity were enlarged. 
Further radiographs and osseous scintigraphy imaging of 
the whole body disclosed additional metastases to the orbit, 
the frontal sinus wall and left knee. Bilateral bone marrow 
aspirates revealed metastatic NB (Fig 4). Based on these fin-
dings, the tumor was classified as stage IV disease according 
to the International Neuroblastoma Staging System INSS 
(chromosomal and molecular work up were not available)
In consideration of the poor prognosis and lack of adequate 
treatment at this stage of disease, a palliative chemotherapy 
was started. The patient died at home 1 month after initia-
tion of this therapy.
DISCUSSION
Neuroblastoma is the most common extracranial pediatric 
solid tumor and the most common neoplasm in infancy. 
This embryonal neoplasm which takes the form of a lump or 
mass may arise in any site where elements of the sympathetic 
nervous system exist. This solid tumor usually originates 
in the tissue of the adrenal gland (80%), the mediastinum 
(15%) and less than 5% will present in the head and neck 
region (6,7).
Considering the age of  the patient, the rapid onset of 
mandibular enlargement together with radiographic fea-
tures of  bone destruction, differential diagnoses include 
lymphoma, soft tissue sarcoma, osteosarcoma, primitive 
neuroectodermal tumor (PNET), a central malignancy of 
odontogenic origin, or a metastatic tumor. According to 
the International Neuroblastoma Staging System INSS (8) 
the diagnosis of NB can be made by either characteristic 
histopathologic evaluation of tumor tissue or by the pre-
sence of tumor cells in bone marrow aspirate. Elevation of 
urinary levels of vanyllylmandelic acid (VMA) and homo-
vanillic acid (HVA), dopamine, serum ferritin and serum 
levels of neuron specific enolase can help to confirm the 
diagnosis (3,9).
Based on several clinical series, 50% to 60% of patients with 
NB present with disseminated disease (stage IV), a finding 
that is more likely in patients over 1 year of age (1,2,8,10). 
Fig. 1.Swelling of 
the left facial side
Fig. 2. Intraoral view 
revealed the left invol-
vement of  the man-
dible
Fig. 3. CT scan showing ex-
tension of a mass in the left 
side of the mandible with a 
clear osseous destruction.
Fig. 4. Photograph of  bone marrow infiltrate composed of 
small, round, blue cells with occasional rosettes
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Metastases to bone marrow and bones have been described 
in disseminated forms of NB (7,11). Two patterns of ma-
rrow disease can be observed: diffuse type and nodular type 
(12). Bone marrow metastases occur initially in the bone 
marrow sinusoids where tumor cells adhere and extravasate 
to bone marrow parenchyma, resulting in the formation of 
nodular lesions in the medullary cavity. The nodular lesions 
eventually progress to diffuse lesions after proliferation and 
gradually enlarge to erode cancellous bone and invade the 
bone cortex, resulting in bone metastases (12). The bone 
marrow involvement in our case at the time of the initial 
presentation and multiple osteolytic lesions argue strongly 
for a metastatic origin of the mandibular tumor.
Because of the extreme heterogeneous characteristics of 
NB, several prognostic factors have been identified, among 
them patient age, tumor stage, tumor histology and genetic 
abnormalities (2,7,13). Surgery alone is adequate therapy 
for most cases of early stage disease (6). Chemotherapy in 
conjunction with radiation therapy appears to have a cure 
rate of up to 68% for intermediate risk disease (stages IIB, 
III and IV-S disease) (1,14). In contrast, patients with high 
risk disease (age >1 year, stages II and III with N-MYC 
amplification, all patients with stage IV) show progression 
and have poor clinical outcome (2,15). (Table 1)
  
CONCLUSION
Neuroblastoma with metastases to unusual locations, such 
as the mandible, presents a diagnostic problem. However, 
symptoms such as systemic illness, bone pain and unex-
plained teeth displacement in a child should raise suspicion 
of a malignant metastatic tumor. Metastatic work up by 
radiography, bone marrow biopsy and laboratory investi-
gations (eg, catecholamines) are helpful in detecting early 
stage metastasis which is the essential factor for improving 
treatment of neuroblastoma tumors.
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Table 1. International Neuroblastoma Staging System (INSS) (8)
Stage Description 
I Localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor microscopically 
IIA Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph nodes negative for tumor microscopically
IIB
Localized tumor with or without complete gross excision with ipsilateral 
nonadherent lymph nodes positive for tumor; enlarged contralateral lymph 
nodes must be negative microscopically
III
Unresectable unilateral tumor infiltrating across the midline, with or without 
regional lymph node involvement; localized unilateral tumor with contralateral regional lymph node 
involvement; midline tumor with bilateral extension by infiltration (unresectable) or by lymph node 
involvement
IV Dissemination of tumor to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs (except as defined for stage 4S) 
IVS localized primary tumor (as defined for stage 1, 2A, or 2B), with dissemination limited to skin, liver, and/or bone marrow (<10% tumor) in infant younger than 1 year of age 
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